RecruitingPHASE1, PHASE2NCT06429150
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Studying Plasmacytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Intervention
- CAR-T cells(biological)
- Enrollment
- 20 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2024 – 2027
Study locations (2)
- Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
- Hematologist of the Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health, Vladivostok, Russia
Collaborators
The No.2 Clinical Hospital of the Ministry of Health
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06429150 on ClinicalTrials.govOther trials for Plasmacytoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07115667Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow InfiltrationInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06863584SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II TrialSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE2NCT05248633Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary PlasmacytomaPeking Union Medical College Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT04174196A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With PlasmacytomaMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT04166565Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary DiseaseStichting European Myeloma Network
- ACTIVE NOT RECRUITINGPHASE3NCT02544308Trial of Immunomodulatory Therapy in High Risk Solitary Bone PlasmacytomaUniversity College, London